James Cassidy - 06 Oct 2022 Form 3 Insider Report for SpringWorks Therapeutics, Inc. (SWTX)

Role
Chief Medical Officer
Signature
/s/ Francis I. Perier, Jr., Attorney-in-fact
Issuer symbol
SWTX
Transactions as of
06 Oct 2022
Net transactions value
$0
Form type
3
Filing time
11 Oct 2022, 16:01:45 UTC
Next filing
09 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding SWTX Common Stock 25,830 06 Oct 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SWTX Stock Option (Right to Buy) 06 Oct 2022 Common Stock 79,000 $76.30 Direct F2
holding SWTX Stock Option (Right to Buy) 06 Oct 2022 Common Stock 32,568 $59.46 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 10,450 restricted stock units ("RSUs"). Thirty-three percent (33%) of the RSUs shall vest on January 6, 2023, another thirty-three percent (33%) to vest on January 6, 2024 and the remaining thirty-four percent (34%) to vest on January 6, 2025, such that the RSUs are fully vested on January 6, 2025.
F2 Twenty-five percent (25%) of this option vested and became exercisable on September 1, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.
F3 This option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing on January 6, 2022.

Remarks:

Exhibit 24.1 - Power of Attorney